1. Home
  2. CELU vs XGN Comparison

CELU vs XGN Comparison

Compare CELU & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.31

Market Cap

50.7M

Sector

Health Care

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$6.08

Market Cap

140.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELU
XGN
Founded
2016
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
140.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CELU
XGN
Price
$1.31
$6.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$6.00
$13.67
AVG Volume (30 Days)
70.9K
258.8K
Earning Date
11-14-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,578,000.00
$63,599,000.00
Revenue This Year
N/A
$21.76
Revenue Next Year
$76.00
$15.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.08
52 Week Low
$1.00
$2.67
52 Week High
$4.35
$12.23

Technical Indicators

Market Signals
Indicator
CELU
XGN
Relative Strength Index (RSI) 36.20 24.89
Support Level $1.25 $5.93
Resistance Level $2.01 $6.80
Average True Range (ATR) 0.14 0.35
MACD -0.03 0.03
Stochastic Oscillator 13.16 9.47

Price Performance

Historical Comparison
CELU
XGN

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: